TOX and diffuse large B-cell lymphoma: In the most recent work based on genome-wide analysis of 19 primary DLBCL CNS patients, novel recurrent alterations were detected, including TOX and PRKCD, that might help to differentiate primary DLBCL CNS from systemic DLBCL [13].